Dr. Pyott is formerly the Chairman and Chief Executive Officer of Allergan (AGN), where he spent 17 years before the sale of the company to Actavis in 2015. Prior to Allergan, Dr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG.
Dr. Pyott served as the CEO of Allergan from 1998-2015, where he transformed Allergan from a small eye care company into a multi-billion dollar global specialty pharmaceutical and medical device company, driving growth in sales from $1 billion to $7 billion principally by internal innovation, and accompanied by an increase in market capitalization of $68 billion. During his tenure, Dr. Pyott was recognized as one of "The 100 Best Performing CEO's in the World" by Harvard Business Review.
Dr. Pyott is a member of the Boards of Avery Dennison Corporation, Bioniz Therapeutics, BioMarin Pharmaceutical, Alnylam Pharmaceuticals, and a member of the Supervisory Board of Royal Philips in the Netherlands. He is a member of the Governing Board of the London Business School, President of the International Council of Ophthalmology Foundation, and a member of the Advisory Board of the Foundation of the American Academy of Ophthalmology. Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree and an Honorary Degree in Medicine from the University of Edinburgh, and a Master of Business Administration degree from the London Business School. David is also an active philanthropist and created the David E.I. Pyott Foundation to educate physicians on improving patient outcomes.